Skip to Content
Merck

F5006

2-Fluoro-2-deoxy-D-glucose

glycosylation inhibitor, glucose analog

Synonym(s):

2-Deoxy-2-fluoro-D-glucose, FDG, 2-Deoxy-2-fluoro-D-glucose

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C6H11FO5
CAS Number:
29702-43-0
Molecular Weight:
182.15
NACRES:
NA.32
PubChem Substance ID:
24894876
UNSPSC Code:
41116107
MDL number:
MFCD00077527

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

300

assay

≥98.00% (TLC)

form

powder

mol wt

182.15 g/mol

concentration

≤100% (2-Fluoro-2-deoxy-D-glucose)

color

, white to white with yellow cast

mp

174-176 °C

solubility

water: 49.00-51.00 mg/mL, clear, colorless to faintly yellow

storage temp.

2-8°C

SMILES string

OCC1OC(O)C(F)C(O)C1O

InChI

1S/C6H11FO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1H2

InChI key

ZCXUVYAZINUVJD-UHFFFAOYSA-N

Related Categories

General description

2-Fluoro-2-deoxy-D-glucose is non-toxic and a structural analog of glucose, significantly inhibiting glycosylation. As a glucose analog, uptake of 2-Fluoro-2-deoxy-D-glucose is rapid in brain and heart cells.

2-Fluoro-2-deoxy-D-glucose can be taken up by cells but does not undergo metabolic glycolysis.

Application

2-Fluoro-2-deoxy-D-glucose is used as a tracer for rapid tumor detection. It is used as a glucose analog to study glucose uptake in mice with radiation and burn injuries. Oncology therapy studies use FDG in combination with PET (Positron Emission Topography)

Biochem/physiol Actions

Glucose analog that inhibits cellular glycosylation.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000447617
0000447617
0000436161
0000436161
0000436123

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

C J Hoekstra et al.
European journal of nuclear medicine, 27(6), 731-743 (2000-07-20)
[18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) is considered a valuable tool in the diagnosis and staging of cancer. In addition, it seems promising as a technique to monitor response to therapy. Progress is hampered, however, by the fact that various
Frank J Brooks et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 55(1), 37-42 (2013-11-23)
The number of studies in the literature involving quantification of the metabolic heterogeneity seen in (18)F-FDG PET images has increased sharply over recent years. We hypothesized that inclusion of very small regions of interest as unique data points will have
G J Bosman et al.
Biochimica et biophysica acta, 696(3), 285-289 (1982-03-29)
Tunicamycin, 2-deoxy-D-glucose and 2-deoxy-2-fluoro-D-glucose inhibit dimethyl sulfoxide-induced differentiation of Friend cells. This inhibition, characterized by inhibition of hemoglobin synthesis, is accompanied by a specific inhibition of protein glycosylation. The results of cloning experiments indicate that this inhibition specifically affects cells
Khalsa Z Al-Nabhani et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 55(1), 88-94 (2013-12-18)
The aim of this study was to prospectively compare whole-body PET/MR imaging and PET/CT, qualitatively and quantitatively, in oncologic patients and assess the confidence and degree of inter- and intraobserver agreement in anatomic lesion localization. Fifty patients referred for staging
Janet F Eary et al.
The Journal of bone and joint surgery. American volume, 96(2), 152-158 (2014-01-17)
Our previous research investigated the ability of [F-18]fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging results to predict outcome in patients with sarcoma. Tumor uptake of FDG before and after neoadjuvant chemotherapy was predictive of patient outcome. With this background, a
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service